Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Activities
Date:5/17/2011

DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that it had made significant progress with the commercial introduction of MuGard in the radiation oncology and medical oncology communities.  MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating that has been shown to be very effective in the management of oral mucositis, a debilitating side effect of many anticancer treatments.  Access provided the following information related to its ongoing commercialization efforts:

  • Salesforce Management:  At the end of 2010, Access commenced training of third-party MuGard representatives on the product, the oral mucositis condition and sales strategy.  These reps initiated a broad-scale marketing push that will continue throughout 2011.  While greater than 90 reps have received initial MuGard training, efforts to identify and train additional representatives in uncovered or under-resourced geographic areas will also remain a focus throughout the year.

  • MuGard Prescriptions Ramping:  MuGard prescriptions have been ramping consistently for the last several weeks, starting from 10 prescriptions per week and growing to greater than 75 prescriptions per week.  Over 200 doctors to date have prescribed MuGard for their patients and over 80% of these doctors are reoccurring prescribers.  Access believes it has the right team and resources in place to continue ramping prescriptions throughout the year.

  • Reimbursement Activities:  The Company has placed a significant emphasis on its sampling and marketing efforts to build demand, grow oncologist awa
    '/>"/>

  • SOURCE Access Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication
    2. Arstasis Launches New AXERA™ Access Device in the U.S.
    3. SCAI Releases First Report on Transradial Access for Angioplasty and Stenting
    4. New NCPA Study: Medicaid Pharmacy Modernization Could Save States Billions Without Limiting Access
    5. HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
    6. Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations
    7. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
    8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
    9. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
    10. Seymour Hospital Seeks to Meet Meaningful Use Requirements With Prognosis ChartAccess® Comprehensive EHR
    11. New Affiliation Between MinuteClinic and Advocate Health Care Increases Access to Medical Services in Chicagoland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
    (Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
    (Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
    Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
    ... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
    ... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
    Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
    (Date:8/20/2014)... Park Avenue Dental, a leading Florida-based dental ... top graduate of the University of Detroit School of ... website through an ultra-informative blog focused on dental tips ... the blog page is chock full of topics that ... concentrating on important dental care tips including ...
    (Date:8/20/2014)... (PRWEB) August 20, 2014 Ticket Down ... tickets in NYC. In just a week, the U.S. ... King Tennis Center. The event was originally founded in 1881 and ... Rafael Nadal was forced to withdrawal from the event because of ... women’s tournament and will return to New York City with hopes ...
    (Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
    (Date:8/20/2014)... (HealthDay News) -- Pigs, hearts transplanted into baboons survived ... long as previously achieved, researchers report. The work ... animal organs to shorten transplant waiting lists. In ... into baboons, abdomens. The genetic engineering and new methods ... enabled the hearts to survive for more than a ...
    (Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 (HealthDay ... an option, but a new study shows that only about ... reasons women didn,t undergo reconstruction was that they felt it ... were focused on their cancer treatment," said lead researcher Dr. ... Cancer Center, in New York City. Also common was ...
    Breaking Medicine News(10 mins):Health News:Park Avenue Dental Provides Dental Care Tips for World Wide Community on New Website Blog 2Health News:Park Avenue Dental Provides Dental Care Tips for World Wide Community on New Website Blog 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
    ... of ColdFusion Web content management solutions, today announced ... all company records, having grown an average of ... company’s average deal size increased by more than ... profitable since its inception in 1993. The company’s ...
    ... Edwards and breast cancer ... tough times, FERNDALE, Mich., Nov. 13 On Wednesday, ... inspiration in,life,s challenges to the Troy Hilton, at 5500 Crooks ... Parent Magazine are proud to,present this unique opportunity, entitled "An ...
    ... Nov. 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), ... for cardiovascular disease, today announced financial results,for the three ... operating loss for the three months ended September 30, ... $5.5 million, or $0.35 per,share, for the same period ...
    ... of suppressing immune response , , THURSDAY, Nov. 13 (HealthDay ... responses offers promise in efforts to develop treatments for ... a painful, inflammatory form of arthritis -- occurs when ... Foxp3 plays an important role in immune system regulation. ...
    ... with higher levels of phosphate in the blood are ... the coronary arteriesa key indicator of atherosclerosis and future ... 2009 issue of the Journal of the American ... represent a previously unidentified and modifiable cardiovascular risk factor, ...
    ... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... will be held November 18-19, 2008 at The New,York ... Tuesday, November 18th at 11:00 am,ET., HMS Holdings ... in,coordination of benefits and program integrity services for government,healthcare ...
    Cached Medicine News:Health News: PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate 2Health News: PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate 3Health News:Elizabeth Edwards Reschedules Metro Detroit Appearance 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:New Therapy Could Transform Arthritis Treatment 2Health News:High-normal phosphate levels linked to early atherosclerosis 2
    ... This type of anchor is generally utilized when ... directly into the bone. Unlike other anchors that ... anchor does not have that limitation. The only ... is a mallet. The 4.4mm Stainless Steel Anchor ...
    ... Yasushi Nakao, M.D., Smith & Nephew ... flexor,tendon release for fingers and thumbs ... approach is designed to decrease patient ... of releasing the A1 pulley under ...
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Medicine Products: